Abstract:e15511 Background: The aim of this study was to propose a new kind of recurrence risk classification and further establish a prognostic model for resected stage I-III colorectal cancer (CRC). Methods: From 2017 to 2020, 142 patients diagnosed with stage I-III CRC at Peking University Shougang Hospital were recruited for this study. Tissues and paired white blood cells were analyzed with a 733-gene NGS panel, and peripheral plasma obtained 7-10 days after surgery was analyzed with a 127-gene ultra-deep target panel in a CLIA-certified laboratory. The relationship between the postoperative ctDNA status, clinicopathological features and recurrence-free survival (RFS) was identified by log-rank test and Cox regression analysis. Results: In total, 108 patients successfully completed both tissue and postoperative plasma NGS tests, of which 17 patients were postoperatively positive for ctDNA (tumor-informed, ≥1 somatic mutation). Postoperative ctDNA positivity was independently associated with poorer RFS (HR = 8.4, P < 0.0001). Postoperative recurrence rates were significantly higher in ctDNA-positive patients than ctDNA-negative patients (76.5% vs 16.5%, P < 0.0001). Univariate analysis showed that, in addition to ctDNA status, stage, vascular invasion, neural invasion, and preoperative CEA were all significantly associated with worse RFS (P < 0.05). Furthermore, in a COX regression model, the contribution of these clinicopathological factors to RFS has been adjusted. The model showed good discrimination [the concordance index (c-index): 0.811] of recurrence. Clinically high-risk groups according to clinicopathological risk model had significantly poorer RFS than low-risk groups (HR = 10.6, P < 0.001). In the clinicopathological high-risk group, ctDNA-positive patients can still further differentiate the higher risk of recurrence (HR = 3.7, P = 0.0012). There were similar trends in the clinicopathological low-risk group (HR = 6.1, P = 0.066). Combining the clinicopathological model and ctDNA, patients with either clinicopathological high-risk or ctDNA-positive had a significantly poorer RFS, compared with both clinicopathological low-risk and ctDNA-negative (HR = 12.9, P < 0.0001). Conclusions: Postoperative ctDNA can independently predict the risk of recurrence in stage I-III CRC. Combining clinicopathological factors and ctDNA showed superiority for recurrence risk stratification over either alone. This recurrence risk stratification model may serve as a useful clinical tool to help clinicians determine individualized treatment plans for stage I-III CRC patients. However, the model still needs further external cohort validation.

Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer

Exploring prognostic values of DNA ploidy, stroma-tumor fraction and nucleotyping in stage II colon cancer patients

Automated Assessment of DNA Ploidy, Chromatin Organization, and Stroma Fraction to Predict Prognosis and Adjuvant Therapy Response in Patients with Stage II Colorectal Carcinoma.

Prognostic Significance of DNA Ploidy in Patients with Stage II Colorectal Cancer

Prognostic value of DNA ploidy analysis in patients with colorectal cancer

Prognostic and Survival Analysis of 837 Chinese Colorectal Cancer Patients.

Prognostic values of tumor-stroma ratio and tumor-infiltrating lymphocytes in stagesⅡandⅢcolorectal cancer

Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer

Application of RNA Processing Factors for Predicting Clinical Outcomes in Colon Cancer.

Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment

Prognostic analysis of stage IIIC1p cervical cancer patients

Recurrence risk stratification model for patients with stage I-III colorectal cancer based on clinicopathological and postoperative ctDNA predictors.

Combined phenotype of 4 markers improves prognostic value of patients with colon cancer.

Prognostic Factors for Patients with Stage II Colon Cancer: Results of a Prospective Study

Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study

Pathological Risk Factors for Lymph Node Metastasis in Patients with Submucosal Invasive Colorectal Carcinoma

DNA methylation combinations in adjacent normal colon tissue predict cancer recurrence: evidence from a clinical cohort study

Identification and initial validation of neuroendocrine differentiation as a novel prognostic factor in stage II colorectal cancer patients

P-TNM Staging System for Colon Cancer: Combination of P-stage and AJCC TNM Staging System for Improving Prognostic Prediction and Clinical Management

A Recurrence‐predictive Model Based on Eight Genes and Tumor Mutational Burden/microsatellite Instability Status in Stage II/III Colorectal Cancer

Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.